These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26820829)

  • 21. Platelets and primary haemostasis.
    Clemetson KJ
    Thromb Res; 2012 Mar; 129(3):220-4. PubMed ID: 22178577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist.
    Cai TQ; Wickham LA; Sitko G; Michener MS; Raubertas R; Handt L; Chintala M; Seiffert D; Forrest M
    Eur J Pharmacol; 2015 Jul; 758():107-14. PubMed ID: 25857224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of platelet functions by P2 receptors.
    Gachet C
    Annu Rev Pharmacol Toxicol; 2006; 46():277-300. PubMed ID: 16402906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
    Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
    J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys.
    Zhao YM; Jiang M; Ji SD; He Y; Shen F; Li XM; Ruan CG
    Biochem Pharmacol; 2013 Apr; 85(7):945-53. PubMed ID: 23295157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limitations of current therapies to prevent thrombosis: a need for novel strategies.
    Fabre JE; Gurney ME
    Mol Biosyst; 2010 Feb; 6(2):305-15. PubMed ID: 20094648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of platelets in atherothrombosis.
    Jennings LK
    Am J Cardiol; 2009 Feb; 103(3 Suppl):4A-10A. PubMed ID: 19166707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
    Montalescot G
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
    Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
    Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of platelet activation by thrombin: a short history.
    De Candia E
    Thromb Res; 2012 Mar; 129(3):250-6. PubMed ID: 22137742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting platelet receptors in thrombotic and thrombo-inflammatory disorders.
    Vögtle T; Cherpokova D; Bender M; Nieswandt B
    Hamostaseologie; 2015; 35(3):235-43. PubMed ID: 25634564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy in ST-segment elevation myocardial infarction.
    Wong CK; White HD
    Expert Opin Pharmacother; 2011 Feb; 12(2):213-23. PubMed ID: 21226633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency Reversal Strategies for Anticoagulation and Platelet Disorders.
    Levi M
    Front Neurol Neurosci; 2015; 37():51-61. PubMed ID: 26587647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
    Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
    Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.